Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Diazepam

Preparation Calculator

USE IF: Acute seizures and status epilepticus (initial management), alcohol withdrawal, acute agitation, and procedural or rescue sedation per protocol and airway plan.

AVOID IF: Severe respiratory depression, acute CNS depressant intoxication without protected airway and monitoring, and uncontrolled high aspiration risk without mitigation.

Diazepam

Benzodiazepine (anxiolytic, anticonvulsant, emergency sedative)

AdultPediatricERICUNeurologyToxicologyBenzodiazepineHigh-yield

Indication

Seizures (acute) · Status (initial) · Alcohol withdrawal · Agitation · Sedation

At a glance

INDICATIONS (CORE USE)

- Acute seizures / status epilepticus (initial, protocol-based) - Alcohol withdrawal (protocol-based) - Acute agitation - Procedural sedation (selected protocols)

ADULT DOSE (STANDARD)

IV / IM / PR per emergency protocol; repeat as directed with monitoring Oral for withdrawal and selected maintenance contexts (protocol-based)

MAX DOSE

Cumulative max is protocol- and site-specific; avoid stack dosing → respiratory depression

Route

IV · IM · PR · PO

PEDIATRIC DOSE

Protocol-based; weight- and context-specific

Do not miss

Must-not-miss safety points

Major warning

- Respiratory depression → airway and ventilatory risk (especially with opioids, alcohol, and repeat dosing) - Profound CNS depression with co-sedation - Long half-life and active metabolites → accumulation and delayed oversedation with repeated or oral/chronic use - Paradoxical agitation (rare) — reassess if behavior worsens - Physical dependence with repeated use — withdrawal if stopped abruptly after sustained exposure

Indications

USE IF: Acute seizures, status epilepticus (initial management), alcohol withdrawal, acute agitation, and procedural or rescue-level sedation in controlled settings with airway and monitoring resources. AVOID IF: Severe respiratory depression, acute CNS depressant intoxication without a protected airway and adequate monitoring, and high aspiration risk that cannot be mitigated in the acutely sedated patient. INDICATION: Seizures (acute) · Status epilepticus (initial) · Alcohol withdrawal · Acute agitation · Sedation (protocol-driven).

Primary

  • Status epilepticus (initial management, protocol-based)
  • Acute seizures (rescue / acute control)

Secondary

  • Alcohol withdrawal (CIWA/benzodiazepine protocols)
  • Acute agitation (selected etiologies, setting-dependent)
  • Procedural sedation (site-specific, adjunct with airway/physiologic plans)

Dosing

STANDARD (ADULT PO)

STANDARD (ADULT) — all routes are protocol- and site-specific: IV, IM, or PR for emergent neuro indications; oral regimens in withdrawal and maintenance only when the pathway explicitly supports it.

ADULT DOSE

IV/IM/PR (acute): - Dose, push rate, and repeat intervals follow institutional status epilepticus / emergency pathways - Be prepared to escalate to second-line/continuous antiepileptic therapy; diazepam is often initial, not the entire seizure plan Oral (withdrawal and non-acute use): - Fixed-taper or symptom-triggered regimens as defined by the treating service

PEDIATRIC DOSE

Protocol-based, weight- and context-specific dosing; pediatric emergency and neurology guidance required.

MAX DOSE

Cumulative and repeat dosing is protocol-based; the dominant ceiling in practice is **respiratory and hemodynamic safety**, not a single static mg number.

Practical Note

- Rapid onset (especially IV) supports acute seizure control, but the therapeutic window and repeat intervals are protocol-defined - If seizure activity persists, continue **protocol escalation**; plan transition to a **longer-acting antiepileptic strategy** per pathway - Avoid excessive repeat or stacked benzodiazepine doses without **continuous respiratory and hemodynamic** monitoring and clear endpoints - Long half-life and active metabolites: risk of **delayed** oversedation after multiple doses or route switches

Warnings

Clinical warnings

  • Respiratory depression (dose- and co-sedation–dependent) — the critical monitoring target in the ED/ICU
  • Sedation, reduced arousal, and global CNS depression; heightened risk with opioids, alcohol, and other sedatives
  • Hypotension, especially with rapid IV use or volume-depleted/hemodynamically fragile patients
  • Dependence and withdrawal with repeated or prolonged exposure; taper per pathway when used beyond brief rescue
  • Paradoxical agitation and disinhibition in an uncommon subset—reassess diagnosis and restraints/airway as needed per protocol

Adverse effects

  • Drowsiness
  • Respiratory suppression
  • Hypotension
  • Ataxia

Contraindications

  • Severe uncorrected respiratory depression
  • Acute alcohol or CNS depressant intoxication **without** secured airway, monitoring, and resuscitation plan
  • Known hypersensitivity to diazepam or the formulation (e.g., some IV products in benzyl alcohol or propylene glycol contexts per label)

Drug interactions

  • Opioids: profound increase in respiratory depression, apnea, and death—avoid concomitant use in naive patients; lowest effective doses and continuous monitoring if truly unavoidable in structured settings
  • Alcohol: additive CNS and respiratory depression
  • Benzodiazepines, z-drugs, antipsychotic sedatives, and general anesthetics: multiplicative CNS/resp depression

Special populations

Pediatrics

Protocol-based; weight- and context-specific

Pregnancy

Pregnancy: use only for clear maternal benefit with obstetric/neurology and neonatology input (class effects, floppy infant risk near delivery per labeling and pathway).

Lactation

excreted in milk; potential infant sedation—risk-benefit and feeding plan per pharmacy/lactation guidance.

Renal impairment

Hepatic metabolites and conjugates are renally excreted in part; use caution in severe CKD; follow labeling and high-acuity service input when repeating doses.

Hepatic impairment

Hepatic metabolism; risk of **accumulation and prolonged sedation** in hepatic impairment or cirrhosis—dose/rate reduction, avoid bolus stacking, and close neuro/resp monitoring.

Elderly

Increased sensitivity: sedation, falls, confusion, and respiratory depression; prefer lower initial doses, slower push rates, and fall precautions.

Administration

- **IV:** slow administration per protocol to reduce phlebitis, hypotension, and respiratory arrest—use appropriate dilution, line type, and push rate for the institutional standard - **IM:** when IV not immediately available, per resuscitation pathway - **Rectal:** established role in out-of-hospital and selected in-hospital seizure rescue when no IV/IO access; device training matters - **PO:** for withdrawal tapers and non-acute use only when the clinical context matches the pathway - Continuous attention to **airway, SpO2/ventilation, and blood pressure** during and after any sedating dose

Monitoring

  • Monitor: - Respiratory rate, effort, and oxygenation (highest priority) - Airway and aspiration risk when deeply sedated - Level of consciousness and seizure control - Blood pressure (notably with IV use)
  • Recheck: - After every dose in the acute resuscitation window - Continuously in ICU/ER contexts where institutional policy mandates extended observation after benzodiazepines and co-sedation
  • Hold / escalate or reverse per pathway if: - Respiratory depression, apnea, or inability to protect airway - Hemodynamically significant hypotension - Deteriorating level of consciousness without resolving seizure (move to next-line plan)

Overdose / toxicity

Clinical Picture

CNS and respiratory depression ranging from somnolence to coma, with apnea and related hypoxic injury; hypotension and cardiovascular collapse in severe cases.

Immediate Actions

**Airway first:** jaw thrust, BVM, and intubation as indicated; 100% oxygen, ventilatory support, IV access, and reversal of contributing agents per toxicology. Continuous cardiac and capnography monitoring when available.

Antidote

Flumazenil: **caution** — may precipitate seizures in patients on long-term benzodiazepines, chronic alcohol, or concomitant proconvulsant states; use only in selected supervised settings with resuscitation capability and a clear risk-benefit plan.

Decontamination

Primarily supportive; oral exposures managed per toxicology with airway protected if interventions considered.

Escalation

ICU admission, advanced airway/ventilatory support, pressors as indicated, and continuous EEG/neuro monitoring in refractory or unclear seizure versus toxic-metabolic overlap.

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield

  • Front-line for **status epilepticus initial** benzodiazepine rounds in many pathways — not the end of the seizure care plan; bridge to durable maintenance/continuous therapy as indicated
  • After emergent control, most pathways call for a **longer-acting antiepileptic** strategy — match local algorithm

Clinical

  • Rectal diazepam is a lifeline in **no-IV, pre-hospital** seizure rescue when available and the team is trained for device and dosing
  • In persistent seizures, the failure mode is **under-treatment of status** versus **toxicity** — the pathway must spell out both escalation and limits

Safety

  • Most dangerous co-exposure: **benzodiazepine + opioid** in the same unmonitored, unsupervised, or out-of-ICU context — expect apnea
  • Repeat doses: watch for the **late second wave** of CNS/resp depression from parent drug + active metabolites

Pharmacy Tool

Preparation Calculator

Diazepam 1 mg/mL oral suspension

suspension · oral

Acknowledge the statements above to unlock volume scaling and ingredient quantities.

Pharmacokinetics

- **Long half-life** among benzodiazepines; duration of CNS and respiratory effects can outlast a single “clinical look” - **Active metabolites** (e.g., desmethyldiazepam) extend apparent duration—especially in repeated dosing, elderly, and hepatic impairment - Lipid-soluble: tissue redistribution influences perceived onset/offset, particularly after IV or large acute loads

Mechanism of action

- Allosteric enhancement of GABA-A receptor function → increased chloride conductance, neuronal hyperpolarization, and **net CNS inhibition** (anticonvulsant, anxiolytic, and sedating effects).

Common brand names

Saudi Arabia

Valium, Stesolid

Global

Valium (example), Diastat / rectal (example), Diazemuls (emulsion, regional), Diazepam (generic)

Common trade names are curated examples only — formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

Global data (no country-specific data available)

  • Follow local antimicrobial stewardship policy, hospital formulary, and national resistance guidance.
  • Confirm dosing, stock, and restrictions with institutional pharmacy and current product labeling.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • Institutional status epilepticus, neurocritical care, and alcohol withdrawal (CIWA) pathways
  • AAN / AES / NCS-style guidance on time-sensitive seizure care where adopted locally; ER triage and sedation policies
  • FDA / SFDA labeling and product-specific IV diluent / valproate incompatibilities per insert
  • Regional emergency medicine, anesthesia, and controlled-substance co-prescribing rules